Triastek receives strategic investment from Lingang Digital Economy Fund and Shanghai Minhang financial investment arm

Triastek, a Jiangsu-based developer of 3D printed oral drug formulations, was named among five healthcare deals in a July 13 investment roundup covering mainland China, receiving a strategic investment from Lingang Digital Economy Fund and the Shanghai Minhang District financial investment arm. The specific deal size for Triastek was not disclosed. The broader healthcare tranche totaled roughly 457 million yuan across five domestic companies, part of a 21-deal, 2.172 billion yuan daily roundup spanning healthcare and other sectors.

Triastek's core technology is Melt Extrusion Deposition, a pharmaceutical 3D printing process used to manufacture oral solid dosage forms with programmable release profiles, a narrow but technically demanding corner of additive manufacturing distinct from metal or industrial polymer AM. The involvement of a state-linked Lingang fund and a district-level financial investment vehicle points to continued domestic capital support for precision drug manufacturing infrastructure in China rather than a one-off venture round. Given the undisclosed amount, the more informative signal will be whether Triastek later confirms use of proceeds toward manufacturing capacity or regulatory filings with NMPA or FDA.